Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H21NO |
Molecular Weight | 255.3547 |
Optical Activity | ( - ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2
InChI
InChIKey=VHGCDTVCOLNTBX-QGZVFWFLSA-N
InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
Molecular Formula | C17H21NO |
Molecular Weight | 255.3547 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/pro/atomoxetine.html
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/pro/atomoxetine.html
Atomoxetine is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder. The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter. Most common adverse reactions are: nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence, constipation, dry mouth, dizziness, erectile dysfunction, and urinary hesitation. Atomoxetine is a substrate for CYP2D6 and hence concurrent treatment with CYP2D6 inhibitors such as bupropion (Wellbutrin) or fluoxetine (Prozac) is not recommended, as this can lead to significant elevations of plasma atomoxetine levels.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800000561
Curator's Comment: # Eli Lilly
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
5.0 nM [Ki] | |||
Target ID: CHEMBL228 |
77.0 nM [Ki] | ||
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12431845 |
1451.0 nM [Ki] | ||
Target ID: Q00959 Gene ID: 24409.0 Gene Symbol: Grin2a Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20423340 |
1.58 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | STRATTERA Approved UseAttention-Deficit/Hyperactivity Disorder (ADHD) STRATTERA is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The efficacy of STRATTERA Capsules was established in seven clinical trials in outpatients with ADHD: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see Clinical Studies (14) Launch Date2002 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
414.82 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23812961 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ATOMOXETINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2693.29 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23812961 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ATOMOXETINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.64 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23812961 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ATOMOXETINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
ATOMOXETINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Overview
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 15.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Non-stimulant treatment for Attention-Deficit/Hyperactivity Disorder. | 2002 |
|
Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. | 2002 |
|
Gateways to clinical trials. | 2002 Dec |
|
Gateways to clinical trials. | 2002 Nov |
|
Glutamatergic changes with treatment in attention deficit hyperactivity disorder: a preliminary case series. | 2002 Winter |
|
Cardiovascular effects of atomoxetine in children, adolescents, and adults. | 2003 |
|
Atomoxetine. | 2003 |
|
Pharmacologic treatment approaches for children and adolescents with posttraumatic stress disorder. | 2003 Apr |
|
Non-stimulant treatment of attention-deficit/hyperactivity disorder. | 2003 Apr |
|
Updates on attention deficit hyperactivity disorder, child abuse and neglect, and sudden infant death syndrome. | 2003 Apr |
|
Atomoxetine and pregnancy. | 2003 Aug |
|
Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. | 2003 Dec |
|
Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. | 2003 Feb |
|
Atomoxetine (strattera) for ADHD. | 2003 Feb 3 |
|
Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. | 2003 Mar |
|
Strattera approved to treat ADHD. | 2003 Mar-Apr |
|
Gateways to clinical trials. | 2003 May |
|
Atomoxetine for attention deficit/hyperactivity disorder. | 2003 May |
|
Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. | 2003 Spring |
|
Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. | 2004 |
|
Impact of ADHD and its treatment on substance abuse in adults. | 2004 |
|
ADHD treatment across the life cycle. | 2004 |
|
Seizures and prolonged QTc with atomoxetine overdose. | 2004 Apr |
|
A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. | 2004 Aug |
|
Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. | 2004 Aug |
|
Synthesis and biological evaluation of the major metabolite of atomoxetine: elucidation of a partial kappa-opioid agonist effect. | 2004 Aug 2 |
|
[Tourette syndrome: an analysis of its comorbidity and specific treatment]. | 2004 Feb |
|
[New therapeutic options in the treatment of attention deficit/hyperactivity disorder]. | 2004 Feb |
|
New drugs 04, part 1. | 2004 Feb |
|
Atomoxetine treatment of attention-deficit/hyperactivity disorder. | 2004 Jan |
|
Gateways to clinical trials. | 2004 Jan-Feb |
|
The use of atomoxetine adjunctively in fibromyalgia syndrome. | 2004 Jul |
|
New options in the pharmacological management of attention-deficit/hyperactivity disorder. | 2004 Jul |
|
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. | 2004 Jul |
|
The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. | 2004 Jun |
|
Acute oxcarbazepine and atomoxetine overdose with quetiapine. | 2004 Jun |
|
Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. | 2004 Jun |
|
[Attention-deficit/hyperactivity disorder (ADHS) in adulthood]. | 2004 Mar-Apr |
|
Atomoxetine hydrochloride. | 2004 May |
|
Potential noradrenergic targets for cognitive enhancement in schizophrenia. | 2004 May |
|
Adrenergic alpha 2C receptor genomic organization: association study in adult ADHD. | 2004 May 15 |
|
New drugs for the treatment of attention-deficit/hyperactivity disorder. | 2004 Nov |
|
Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. | 2004 Nov |
|
Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. | 2004 Nov 15 |
|
A lifetime of distractions. ADHD is no longer just a children's disease. Many adults are being diagnosed and treated for the condition. | 2004 Oct |
|
[Atomoxetine for the treatment of attention-deficit/hyperactivity disorder]. | 2004 Oct |
|
Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. | 2004 Sep |
|
Gateways to clinical trials. | 2004 Sep |
|
Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. | 2004 Sep 6 |
|
Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys. | 2005 Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/atomoxetine.html
Atomoxetine should be initiated at a total daily dose of approximately 0.5 mg/kg and increased after a minimum of 3 days to a target total daily dose of approximately 1.2 mg/kg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. No additional benefit has been demonstrated for doses higher than 1.2 mg/kg/day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20423340
Electrophysiological recordings was performed with the extracellular standard solution at different membrane potentials ranging from -80 mV to +40 mV while the concentration of the agonists (100 uM NMDA/10 uM glycine) and the antagonist (25 uM atomoxetine) were kept constant. The inhibitory effect was clearly voltage-dependent, so that the inhibition was attenuated by depolarization.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:16:46 GMT 2025
by
admin
on
Wed Apr 02 09:16:46 GMT 2025
|
Record UNII |
ASW034S0B8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N06BA09
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
||
|
LIVERTOX |
NBK548671
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
||
|
WHO-VATC |
QN06BA09
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
||
|
NCI_THESAURUS |
C265
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
||
|
NDF-RT |
N0000175695
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
||
|
NDF-RT |
N0000000102
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
54841
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
C74141
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
83015-26-3
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
100000090524
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
7352
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
ASW034S0B8
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
SUB20597
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
38400
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | RxNorm | ||
|
ASW034S0B8
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
7118
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
Atomoxetine
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
CHEMBL641
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
ATOMOXETINE
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
DB00289
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
m2124
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | Merck Index | ||
|
331697
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
C041930
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
127342
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
256
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
5354
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY | |||
|
DTXSID9044297
Created by
admin on Wed Apr 02 09:16:46 GMT 2025 , Edited by admin on Wed Apr 02 09:16:46 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
NON-COMPETITIVE
IC50
|
||
|
RACEMATE -> ENANTIOMER |
|
||
|
TARGET -> INHIBITOR |
|
||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
EXCRETED UNCHANGED |
FECAL; URINE
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE LESS ACTIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||